Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.34 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | EPOR | P19235 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18317884 | 1.00 | HTR2A (0.39) | HTR2AHDAC4HDAC2HDAC8GRIK1 | |
| SCHEMBL16334647 | 0.83 | HDAC4 (0.36) | HDAC4HDAC2HDAC8CHRM2CHRM1 | |
| SCHEMBL16334648 | 0.83 | HDAC4 (0.36) | HDAC4HDAC2HDAC8CHRM2CHRM1 | |
| SCHEMBL27796753 | 0.82 | ALDH1A1 (0.41) | HDAC4HDAC2HDAC8 | |
| SCHEMBL6714738 | 0.82 | HTR2A (0.44) | HTR2AHDAC4HDAC2HDAC8GRIK1 | |
| SCHEMBL6660329 | 0.82 | HTR2A (0.44) | HTR2AHDAC4HDAC2HDAC8GRIK1 | |
| SCHEMBL9580067 | 0.80 | HDAC4 (0.42) | HDAC4HDAC2HDAC8 | |
| SCHEMBL16335221 | 0.78 | MAOB (0.36) | HDAC4HDAC2HDAC8 | |
| SCHEMBL16335220 | 0.78 | MAOB (0.36) | HDAC4HDAC2HDAC8 | |
| SCHEMBL180401 | 0.75 | HDAC4 (0.43) | HDAC4HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3013782-B1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2018-10-03 | — | — | EP | disclosed |
| US-9708570-B2 | Organic compounds | Givaudan, S.A. (CH) | 2017-07-18 | — | — | US | disclosed |
| US-20160369205-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160369205-A1 | ORGANIC COMPOUNDS | PAH, AQP3, HPD | HTR2A 1099/4885HDAC4 1513/4885HDAC2 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.